Abstract

e19548 Background: Post-transplant lymphoproliferative disorder (PTLD) is the most common malignancy after solid organ transplantation (SOT) in adults, apart from skin cancer. It is a serious and potentially fatal complication of chronic immunosuppression in SOT recipients. Methods: Institutional electronic health record (EHR), Epic was queried for PTLD patients evaluated at the University of Cincinnati Cancer Center 1991 - 2020. Relationships between clinical characteristics and time from diagnosis to death were assessed using t-test and ANOVA, with SAS 9.4. Overall survival (OS) was evaluated by Kaplan Meier estimates, from the date of PTLD diagnosis to death or last follow-up. Results: Sixty patients were identified with PTLD in the study period. A higher proportion of males (65%) and Caucasians (92%) was noted. The most common type of transplants were kidney (40%) and liver (32%). The median time from transplant to PTLD was 7.3 y and the median age at diagnosis was 54.5 y. The majority had monomorphic PTLD (60%) and presented as Stage IV (25%) or with end-organ dysfunction (67%). Most had extranodal involvement (67%), with GI (23%) being the most frequently involved site. EBV was positive in 32%. Immunosuppression was changed in 75% of the patients and most received rituximab-chemotherapy (55%), with two-thirds achieving a response. The 2-year OS was 55%. Gender (males 44%, females 14%; p = 0.0216), transplant type (lung 67%, liver 53%, kidney 21%, kidney-pancreas 0%; p = 0.0183) and treatment response (CR 20%, PR 29%, no response 100%; p = 0.0003) were significantly associated with mortality. Median time from PTLD diagnosis to death was 5.2 mo, being significantly shorter in liver transplant recipients (p < 0.0001), those managed by observation only (p < 0.0001) or with end-organ dysfunction at diagnosis (0.0072). A similar trend was noted in males, non-Caucasians, HLA-mismatch, and polymorphic PTLD, but this was statistically nonsignificant. Conclusions: This investigation highlights the prognostic risk factors of PTLD, that could be helpful in the management of the patients and guiding future research.[Table: see text]

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call